Hologic wraps up $3.8B Gen-Probe buy

The deal is done. Hologic ($HOLX) is now the new owner of molecular diagnostics rising star Gen-Probe ($GPRO), after closing the $3.8 billion deal Wednesday.

Moving ahead, Bedford, MA-based Hologic now predicts accelerated growth and presence in the molecular diagnostics space, with a particular focus on tests concerning sexually transmitted diseases. Gen-Probe brings plenty of new tests for STDs, like chlamydia, gonorrhea, and human papillomavirus, to the table. The acquisition is also expected to lead to about $75 million in "cost synergies" within three years.

On Wednesday, the same day that the deal closed, Hologic notified Wisconsin state officials that it would close a factory in Madison by fall 2014, according to WTAQ, slashing 130 jobs.

The Hologic/Gen-Probe transaction also appears to be one of the friendlier M&A deals in recent months. Gen-Probe's chairman and CEO Carl Hull isn't going anywhere, for example. He plans to stay for at least 15 months as a senior vice president and general manager of the combined companies' diagnostics business. And Hologic was pushing before the deal-closing to retain a number of other Gen-Probe managers.

Hologic said its net income fell to $23.6 million during the third quarter, compared to $36.2 million in the fiscal 2011 third quarter, despite a healthy hump in revenue from digital mammography and diagnostics services and products. Even without the Gen-Probe deal factored in, however, Hologic predicts its Q4 revenues will expand.

- read the announcement
- check out the WTAQ story

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.